Table1 Comparison of clinical characteristics between patients with and without hyperuricemia.
Variables | All subjects n = 474,725 | Hyperuricemia (−) n = 423,568 | Hyperuricemia (+) n = 51,157 | P value |
|---|---|---|---|---|
Age | 62.8 ± 8.8 | 62.9 ± 8.8 | 61.5 ± 9.4 | < 0.0001 |
Male, n (%) | 203,087 (43%) | 158,620 (37%) | 44,467 (87%) | < 0.0001 |
BMI, kg/m2 | 23.5 ± 3.4 | 23.3 ± 3.4 | 25.1 ± 3.5 | < 0.0001 |
Hypertension, n (%) | 279,480 (59%) | 242,236 (57%) | 37,244 (73%) | < 0.0001 |
Dyslipidemia, n (%) | 234,204 (49%) | 202,347 (48%) | 31,857 (62%) | < 0.0001 |
Diabetes mellitus, n (%) | 44,592 (9.4%) | 39,296 (9.3%) | 5,296 (10.4%) | < 0.0001 |
Smoking, n (%) | 72,586 (15%) | 59,474 (14%) | 13,112 (26%) | < 0.0001 |
Previous cardiovascular disease, n (%) | 16,705 (3.5%) | 14,262 (3.4%) | 2,443(4.8%) | < 0.0001 |
Previous cerebrovascular disease, n (%) | 25,646 (5.4%) | 22,102 (5.2%) | 3,544 (6.9%) | < 0.0001 |
Biochemical data | ||||
Uric acid (mg/dL) | 5.3 ± 1.0 | 5.0 ± 1.1 | 7.9 ± 0.8 | < 0.0001 |
eGFR (ml/min/1.73 m2) | 75.6 ± 15.4 | 79.5 ± 15.4 | 58.3 ± 15.3 | < 0.0001 |
HbA1c (%) | 5.38 ± 0.74 | 5.38 ± 0.75 | 5.36 ± 0.64 | 0.0001 |
Fasting blood glucose (mg/dL) | 98 ± 22 | 98 ± 22 | 102 ± 20 | < 0.0001 |
Medications | ||||
Anti-hypertensive drug, n (%) | 141,321 (30%) | 121,392 (29%) | 19,929 (39%) | < 0.0001 |
Anti-diabetic drug, n (%) | 26,206 (5.5%) | 23,330 (5.5%) | 2,876 (5.6%) | 0.2876 |
Anti-dyslipidemia drug, n (%) | 69,607 (14.7%) | 63,581 (15.0%) | 6,026 (11.8%) | < 0.0001 |
